Home > Company News > Cyprotex extends its metabolite identification service to support human clinical samples
Cyprotex extends its metabolite identification service to support human clinical samples
September 13th 2016
Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex extends its metabolite identification service to support human clinical samples
Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today that it is extending its metabolite profiling and identification service to include the ability to receive, store and analyse human plasma or urine samples for the presence of drug metabolites. Metabolites are by-products of drug metabolism in the body. These metabolites may be active or inactive against the therapeutic target and so affect efficacy, or may be more toxic or less toxic than the administered drug and so influence adverse effects. Therefore, identifying which metabolites are formed in the body, the extent to which they are formed, and how they are excreted is important in understanding these processes.
Cyprotex already support clinical stage in vitro drug-drug interaction studies. Having authorisation to accept and analyse human samples for exploratory metabolite identification studies will further enhance our capabilities for supporting clinical development stage projects.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “Cyprotex have specialist expertise in metabolite profiling and structural elucidation, and are considered to be a centre of excellence for these studies. We have recently bolstered our capabilities with two AB Sciex TripleTOF® 6600 instruments which, along with our existing Waters Xevo® G2-S QTof instrument, provide an impressive range of high resolution accurate mass spectrometers for the sensitive analysis of metabolites.’
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemTarget, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com